Stockscreener 앱 받기
9.80
0.72%
0.07
시간 외 거래:
9.80
전일 마감가:
$9.73
열려 있는:
$9.68
하루 거래량:
3.36M
Relative Volume:
1.31
시가총액:
$2.93B
수익:
$493.67M
순이익/손실:
$-104.69M
주가수익비율:
-15.31
EPS:
-0.64
순현금흐름:
$-31.51M
1주 성능:
+4.70%
1개월 성능:
+2.19%
6개월 성능:
+0.00%
1년 성능:
-23.68%
1일 변동 폭
$9.60
$9.88
1주일 범위
$9.275
$9.99
52주 변동 폭
$9.02
$14.57
아미쿠스 테라 Stock (FOLD) Company Profile
명칭
Amicus Therapeutics Inc
전화
(609) 662-2000
주소
47 HULFISH STREET, PRINCETON, NJ
FOLD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
9.80 | 2.93B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
아미쿠스 테라 Stock (FOLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 개시 | Jefferies | Buy |
| 2024-05-30 | 개시 | Wells Fargo | Overweight |
| 2024-05-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 재개 | Goldman | Neutral |
| 2022-01-14 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-30 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 재개 | BTIG Research | Buy |
| 2021-05-27 | 개시 | Needham | Hold |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 개시 | Stifel | Hold |
| 2021-02-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-02-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-17 | 개시 | H.C. Wainwright | Buy |
| 2019-06-05 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 개시 | Janney | Buy |
| 2019-01-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 개시 | Citigroup | Neutral |
| 2018-08-17 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
| 2017-09-13 | 재확인 | Chardan Capital Markets | Buy |
| 2017-08-10 | 재확인 | Chardan Capital Markets | Buy |
| 2017-01-24 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 개시 | BofA/Merrill | Buy |
| 2016-04-14 | 개시 | Robert W. Baird | Neutral |
| 2016-04-12 | 재확인 | Chardan Capital Markets | Buy |
| 2015-09-16 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 재확인 | Chardan Capital Markets | Buy |
모두보기
아미쿠스 테라 주식(FOLD)의 최신 뉴스
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Fabry Disease Treatment Market Growth in Future Scope 2024-2031 - openPR
FOLD: 3 High-Growth Biotech Stocks to Watch - StockNews.com
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to "Hold" at StockNews.com - MarketBeat
Y Intercept Hong Kong Ltd Has $374,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Up 5.2%Time to Buy? - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lessened by Orion Portfolio Solutions LLC - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down – Here’s What Happened - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap DownTime to Sell? - MarketBeat
Morgan Stanley upgrades PTC, cuts Immuneering, Amicus (PTCT:NASDAQ) - Seeking Alpha
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? - Yahoo Finance
Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy? - MSN
Morgan Stanley cuts Amicus Therapeutics shares to Equalweight rating By Investing.com - Investing.com UK
Amicus Therapeutics' (FOLD) Equal Weight Rating Reaffirmed at Morgan Stanley - MarketBeat
Neo Ivy Capital Management Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 47,310 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Fmr LLC Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Old West Investment Management LLC Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Upgraded to Buy at StockNews.com - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stake Raised by Wellington Management Group LLP - MarketBeat
Point72 Asset Management L.P. Makes New $13.53 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Point72 DIFC Ltd Invests $704,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Janus Henderson Group PLC Trims Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Holdings Cut by Redmile Group LLC - MarketBeat
Parkman Healthcare Partners LLC Has $6.47 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Erste Asset Management GmbH Makes New $1.25 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
BNP Paribas Financial Markets Purchases 225,222 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics CEO Campbell Bradley sells $75,124 in stock - Investing.com India
Amicus Therapeutics CEO Campbell Bradley sells $75,124 in stock By Investing.com - Investing.com UK
Pompe Disease Market is expected to rise at a Significant CAGR, DelveInsight | Pompe Disease Therapies, Clinical trials, Treatment Options, Companies | Genzyme, Sanofi, Amicus Therapeutics, Actus - The Globe and Mail
Pompe Disease Market is expected to rise at a Significant CAGR, - openPR
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Boosted by Edgestream Partners L.P. - MarketBeat
PDT Partners LLC Buys New Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Intech Investment Management LLC Takes $834,000 Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Algert Global LLC Purchases 170,575 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Massachusetts Financial Services Co. MA Has $33.75 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Increases Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Principal Financial Group Inc. Lowers Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
(FOLD) Technical Data - Stock Traders Daily
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc. - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat
Redmile Group, LLC Increases Stake in Amicus Therapeutics Inc - GuruFocus.com
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Acquires Shares in Amic - GuruFocus.com
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated - MSN
Avoro Capital Advisors LLC Adjusts Stake in Amicus Therapeutics Inc - GuruFocus.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by GSA Capital Partners LLP - MarketBeat
아미쿠스 테라 (FOLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):